Automate Your Wheel Strategy on PTCT
With Tiblio's Option Bot, you can configure your own wheel strategy including PTCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTCT
- Rev/Share 22.694
- Book/Share -2.378
- PB -18.6459
- Debt/Equity -2.0974
- CurrentRatio 3.8906
- ROIC 0.3166
- MktCap 3514255380.0
- FreeCF/Share 9.5274
- PFCF 4.7219
- PE 5.8228
- Debt/Assets 0.1467
- DivYield 0
- ROE -0.717
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PTCT | Truist | -- | Buy | -- | $80 | June 17, 2025 |
| Upgrade | PTCT | BofA Securities | Neutral | Buy | -- | $68 | May 9, 2025 |
| Upgrade | PTCT | Citigroup | Sell | Neutral | -- | $40 | May 7, 2025 |
| Upgrade | PTCT | BofA Securities | Underperform | Neutral | $41 | $55 | March 11, 2025 |
| Initiation | PTCT | Scotiabank | -- | Sector Perform | -- | $55 | March 7, 2025 |
| Upgrade | PTCT | Morgan Stanley | Equal Weight | Overweight | $45 | $67 | Dec. 13, 2024 |
| Upgrade | PTCT | RBC Capital Mkts | Sector Perform | Outperform | $39 | $63 | Dec. 3, 2024 |
| Resumed | PTCT | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
| Resumed | PTCT | UBS | -- | Buy | -- | $47 | Aug. 26, 2024 |
News
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
Published: July 29, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.'s PTCT SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).
Read More
These Analysts Increase Their Forecasts On PTC Therapeutics
Published: July 29, 2025 by: Benzinga
Sentiment: Positive
PTC Therapeutics, Inc. PTCT announced it has gained FDA approval for SEPHIENCE on Monday.
Read More
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J. , June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Shareholders to Reach Out
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Shareholders to Learn More About the Investigation
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
Lost Money on PTC Therapeutics, Inc. (PTCT)? Possible Fraud - Contact Levi & Korsinsky Today
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Investors to Learn More About the Investigation
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
Did PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCT
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Shareholders Who Lost Money on PTC Therapeutics, Inc. (PTCT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - PTCT
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Stockholders to Learn More About the Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
Read More
PTC Therapeutics, Inc. (PTCT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
Read More
About PTC Therapeutics, Inc. (PTCT)
- IPO Date 2013-06-20
- Website https://www.ptcbio.com
- Industry Biotechnology
- CEO Matthew B. Klein F.A.C.S.,
- Employees 939